

Cover image: SB203580 administration before disease onset results in increased incidence of arthritis. Immunohistochemistry of phosphorylated p38 (p-p38) in ankylosing enthesitis. Immunoreactivity for p-p38 is detected in enthesal fibroblast-like cell (arrowheads), prehypertrophic chondrocyte-like cells (arrows) and bone. Negative control staining using normal rabbit IgG. Magnification 10× (1) and 20× (2–3). p 726.

Editor

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 9.082

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2012 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Newgen and printed in the UK on acid-free paper from sustainable forests by Buxton Press, Buxton

Annals of the Rheumatic Diseases (ISSN: 0003-4967) is published monthly by BMJ Publishing Group and is distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

- 633** The effects of statins on osteoarthritis structural progression: another glimpse of the Holy Grail?
P G Conaghan

Viewpoint

- 635** The risk of comorbidity
J C Peterson, S A Paget, M S Lachs, M C Reid, M E Charlson

Recommendation

- 638** EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis
D M Gerlag, K Raza, L G M van Baarsen, E Brouwer, C D Buckley, G R Burmester, C Gabay, A I Catrina, A P Cope, F Cornelis, S R Dahlqvist, P Emery, S Eyre, A Finckh, S Gay, J M Hazes, A van der Helm-van Mil, T W J Huizinga, L Klareskog, T K Kvien, C Lewis, K P Machold, J Rönnelid, D van Schaardenburg, G Schett, J S Smolen, S Thomas, J Worthington, P P Tak

Clinical and epidemiological research

- 642** Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study
S Clockaerts, G J V M Van Osch, Y M Bastiaansen-Jenniskens, J A N Verhaar, F Van Glabbeek, J B Van Meurs, H J M Kerckhof, A Hofman, B H Ch Stricker, S M Bierma-Zeinstra
- 648** Use of statins is associated with an increased risk of rheumatoid arthritis
H J I de Jong, O H Klungel, L van Dijk, R J Vandebriel, H G M Leufkens, J W van der Laan, J W Cohen Tervaert, H van Loveren
- 655** Life course body mass index and risk of knee osteoarthritis at the age of 53 years: evidence from the 1946 British birth cohort study
A K Wills, S Blake, R Cooper, R J Coppack, R Hardy, K R Martin, C Cooper, D Kuh
- 661** Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
J Braun, A Deodhar, R D Inman, D van der Heijde, M Mack, S Xu, B Hsu
- 668** Physical activity and physical activity cognitions are potential factors maintaining fatigue in patients with primary Sjögren's syndrome
E J M Wouters, N van Leeuwen, E R Bossema, A A Kruize, H Bootsma, J W J Bijlsma, R Geenen
- 674** Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
C Wagner, S Visvanathan, J Braun, D van der Heijde, A Deodhar, B Hsu, M Mack, M Elashoff, R D Inman
- 681** Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort
S Lillegraven, F H M Prince, N A Shadick, V P Bykerk, B Lu, M L Fries, C K Iannaccone, T K Kvien, E A Haavardsholm, M E Weinblatt, D H Solomon
- 687** Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
J S Smolen, J C M Avila, D Aletaha
- 694** Analysis of autosomal genes reveals gene–sex interactions and higher total genetic risk in men with systemic lupus erythematosus
T Hughes, A Adler, J T Merrill, J A Kelly, K M Kaufman, A Williams, C D Langefeld, G S Gilkeson, E Sanchez, J Martin, S A Boackle, A M Stevens, G S Alarcón, T B Niewold, E E Brown, R P Kimberly, J C Edberg, R Ramsey-Goldman, M Petri, J D Reveille, L A Criswell, L M Vilá, C O Jacob, P M Gaffney, K L Moser, T J Vyse, M E Alarcón-Riquelme, BIOLUPUS Network, J A James, B P Tsao, R H Scofield, J B Harley, B C Richardson, A H Sawalha
- 700** Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
J Sieper, D van der Heijde, M Dougados, L S Brown, F Lavie, A L Pangan
- 707** Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study
R Knevel, G Gröndal, T W J Huizinga, A W Visser, H Jönsson, A Vileingson, Á J Geirsson, K Steinsson, A H M van der Helm-van Mil
- 710** Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy
Y Ichimura, T Matsushita, Y Hamaguchi, K Kaji, M Hasegawa, Y Tanino, Y Inokoshi, K Kawai, T Kanekura, M Habuchi, A Igarashi, R Sogame, T Hashimoto, T Koga, A Nishino, N Ishiguro, N Sugimoto, R Aoki, N Ando, T Abe, T Kanda, M Kuwana, K Takehara, M Fujimoto
- 714** A high density SNP genotyping approach within the 19q13 chromosome region identifies an association of a CNOT3 polymorphism with ankylosing spondylitis
R Díaz-Peña, A M Aransay, B Suárez-Álvarez, J Bruges-Armas, N Rodríguez-Ezpeleta, M Regueiro, F M Pimentel-Santos, J Mulero, A Sánchez, E Collantes, R Queiro, J Ballina, H Alves, C López-Larrea

MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics


www.publicationethics.org.uk




When you have finished with this please recycle it

- 718** Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry
 C P Denton, T Krieg, L Guillemin, B Schwierin, D Rosenberg, M Silkeby, M Zulfak, M Matucci-Cerinic, on behalf of the DUO Registry investigators

Basic and translational research

- 722** Blocking p38 signalling inhibits chondrogenesis *in vitro* but not ankylosis in a model of ankylosing spondylitis *in vivo*
 K Braem, F P Luyten, R J U Lories
- 729** Endothelial cells present an innate resistance to glucocorticoid treatment: implications for therapy of primary vasculitis
 P Koenen, K Barczyk, M Wolf, J Roth, D Viemann
- 737** Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis
 N Reich, M Tomcik, P Zerr, V Lang, C Dees, J Avouac, K Palumbo, A Horn, A Akhmetshina, C Beyer, W Xie, B L Bennett, O Distler, G Schett, J H W Distler
- 746** Changes in matrix protein biochemistry and the expression of mRNA encoding matrix proteins and metalloproteinases in posterior tibialis tendinopathy
 A N Corps, A H N Robinson, R L Harrall, N C Avery, V A Curry, B L Hazleman, G P Riley
- 753** Impact of IL-1 signalling on experimental uveitis and arthritis
 S R Planck, A Woods, J S Clowers, M J Nicklin, J T Rosenbaum, H L Rosenzweig

- 761** β -catenin is a central mediator of pro-fibrotic Wnt signalling in systemic sclerosis
 C Beyer, A Schramm, A Akhmetshina, C Dees, T Kireva, K Gelse, S Sonnylal, B de Crombrughe, M M Taketo, O Distler, G Schett, J H W Distler
- 768** Combination of IL-17 and TNF α induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells
 A Hot, V Lenief, P Miossec
- 777** Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at *MSH5*, *HLA-DPB1* and *HLA-G*
 M M A Fernando, J Freudenberg, A Lee, D L Morris, L Boteva, B Rhodes, M F Gonzalez-Escribano, M A Lopez-Nevot, S V Navarra, P K Gregersen, J Martin, IMAGEN,* T J Vyse
- 785** Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis
 A Horn, T Kireva, K Palumbo-Zerr, C Dees, M Tomcik, C Cordazzo, P Zerr, A Akhmetshina, M Ruat, O Distler, C Beyer, G Schett, J H W Distler

Letter

- 790** Reduced vitamin D levels are associated with autoimmune response in tuberculosis patients
 W Li, R Zhang, K Zhang, L Song, P Hong, Y Zhang, J Xie, L Wang, J Li